Pathogenesis of COVID-19 from a cell biology perspective.
Reads0
Chats0
TLDR
COVID-19 can be understood by the region of the lung that is infected and can be divided into three phases that correspond to different clinical stages of the disease, which will be confined to the conducting airways and severe disease will involve the gas exchange portion of the lungs.Abstract:
COVID-19 can be understood by the region of the lung that is infected. Mild disease will be confined to the conducting airways and severe disease will involve the gas exchange portion of the lung.read more
Citations
More filters
Journal ArticleDOI
Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens inflammation in airway cells.
Ria Goswami,Veronica S. Russell,Joshua J. Tu,Philip F. Hughes,Francine Kelly,Stephanie N. Langel,Justin Steppe,Scott M. Palmer,Timothy A.J. Haystead,Maria Blasi,Sallie R. Permar +10 more
TL;DR: It is demonstrated that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index.
Journal ArticleDOI
Identification of Images of COVID-19 from Chest X-rays Using Deep Learning: Comparing COGNEX VisionPro Deep Learning 1.0™ Software with Open Source Convolutional Neural Networks.
TL;DR: In this article, the authors used the deep learning software, VisionPro Deep Learning, to classify chest X-rays from the COVIDx dataset and achieved an overall F1 score of 94.0% and on the segmented lungs, it achieved an F1score of 95.3%.
Journal ArticleDOI
Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
Francesco Cattel,Susanna Giordano,Cecilia Bertiond,Tommaso Lupia,Silvia Corcione,M Scaldaferri,Lorenzo Angelone,Francesco Giuseppe De Rosa +7 more
TL;DR: The use of exogenous pulmonary surfactant seems to be promising as an additional therapy for the treatment of inflammatory lung diseases, especially ARDS, especially COVID-19-associated ARDS patients as mentioned in this paper.
Journal ArticleDOI
A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development
TL;DR: A prototype QSP model is presented that captures two physiologically relevant outcomes following infection: a “healthy” immune response that appropriately defends against the virus, and an uncontrolled alveolar inflammatory response that is characteristic of acute respiratory distress syndrome.
Journal ArticleDOI
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19
Lyn R. Frumkin,Michaela Lucas,Curtis L. Scribner,Nastassja Ortega-Heinly,Jayden Rogers,Ga-Chen Yin,Trevor J. Hallam,Alice Yam,Kristin Bedard,Rebecca Begley,Courtney A. Cohen,Catherine V. Badger,Shawn A. Abbasi,John M. Dye,B C McMillan,Michael Wallach,Traci L. Bricker,Astha Joshi,Adrianus C. M. Boon,Suman Pokhrel,B. R. Kraemer,Lucia Lee,S. Kargotich,Mahima Agogiya,Tom St. John,Daria Mochly-Rosen +25 more
TL;DR: Antibodies from eggs of hens that were administered the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein were developed for use as nasal drops to capture the virus on the nasal mucosa and surprisingly had indistinguishable enzyme-linked immunosorbent assay binding against variants of concern that have emerged.
References
More filters
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more
TL;DR: Hospitalised COVID-19 patients are frequently elderly subjects with co-morbidities receiving polypharmacy, all of which are known risk factors for d
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.
Journal ArticleDOI
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.
TL;DR: These analyses provide insights into the receptor usage, cell entry, host cell infectivity and animal origin of 2019-nCoV and may help epidemic surveillance and preventive measures against 2019- nCoV.
Journal ArticleDOI
Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis.
Paul A. Reyfman,James M. Walter,Nikita Joshi,Kishore R. Anekalla,Alexandra C. McQuattie-Pimentel,Stephen Chiu,Ramiro Fernandez,Mahzad Akbarpour,Ching I. Chen,Ziyou Ren,Rohan Verma,Hiam Abdala-Valencia,Kiwon Nam,Monica Chi,SeungHye Han,Francisco J. Gonzalez-Gonzalez,Saul Soberanes,Satoshi Watanabe,Kinola J.N. Williams,Annette S. Flozak,Trevor T. Nicholson,Vince K. Morgan,Deborah R. Winter,Monique Hinchcliff,Cara L. Hrusch,Robert D. Guzy,Catherine A. Bonham,Anne I. Sperling,Remzi Bag,Robert B. Hamanaka,Gökhan M. Mutlu,Anjana Yeldandi,Stacy A. Marshall,Ali Shilatifard,Luís A. Nunes Amaral,Harris Perlman,Jacob I. Sznajder,A. Christine Argento,Colin T. Gillespie,Jane Dematte,Manu Jain,Benjamin D. Singer,Karen M. Ridge,Anna P. Lam,Ankit Bharat,Sangeeta Bhorade,Cara J. Gottardi,G. R. Scott Budinger,Alexander V. Misharin +48 more
TL;DR: The results support the feasibility of discovery-based approaches using next-generation sequencing technologies to identify signaling pathways for targeting in the development of personalized therapies for patients with pulmonary fibrosis.
Related Papers (5)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more